Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis
Journal of Neurochemistry · 2023
DOI: 10.1111/jnc.16005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neurochemistry, 2023. Verfasst von Hideyuki Okano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Induced Pluripotent Stem Cells, Neurodegenerative Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
It has been more than 10 years since the hopes for disease modeling and drug discovery using induced pluripotent stem cell (iPSC) technology boomed. Recently, clinical trials have been conducted with drugs identified using this technology, and some promising results have been reported. For amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, several groups have identified candidate drugs, ezogabine (retigabine), bosutinib, and ropinirole, using iPSCs‐based drug discovery, and clinical trials using these drugs have been conducted, yielding interesting results. In our previous study, an iPSCs‐based drug repurposing approach was utilized to show the potential of ropinirole hydrochloride (ROPI) in reducing ALS‐specific pathological phenotypes. Recently, a phase 1/2a trial was conducted to investigate the effects of ropinirole on ALS further. This double‐blind, randomized, placebo‐controlled study confirmed the safety and tolerability of and provided evidence of its ability to delay disease progression and prolong the time to respiratory failure in ALS patients. Furthermore, in the reverse translational research, in vitro characterization of patient‐derived iPSCs‐motor neurons (MNs) mimicked the therapeutic effects of ROPI in vivo, suggesting the potential application of this technology to the precision medicine of ALS. Interestingly, RNA‐seq data showed that ROPI treatment suppressed the sterol regulatory element‐binding protein 2‐dependent cholesterol biosynthesis pathway. Therefore, this pathway may be involved in the therapeutic effect of ROPI on ALS. The possibility that this pathway may be involved in the therapeutic effect of ALS was demonstrated. Finally, new future strategies for ALS using iPSCs technology will be discussed in this paper.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Keio University School of Medicine, Tokyo, Japan.
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
- Department of Neurology and Stroke, Saitama Medical University International Medical Center, Saitama, Japan.
ORCID-Profile: Hideyuki Okano
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Okano, H., Morimoto, S., Kato, C., Nakahara, J., & Takahashi, S. (2023). Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis. Journal of Neurochemistry. https://doi.org/10.1111/jnc.16005
Vancouver
Okano H, Morimoto S, Kato C, Nakahara J, Takahashi S. Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis. Journal of Neurochemistry. 2023. doi:10.1111/jnc.16005
BibTeX
@article{Okano2023,
author = {Okano, Hideyuki and Morimoto, Satoru and Kato, Chris and Nakahara, Jin and Takahashi, Shinichi},
title = {Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis},
journal = {Journal of Neurochemistry},
year = {2023},
doi = {10.1111/jnc.16005}
}
EUVIMED